SCHEDULE: Morgan Stanley Discloses 9.3% Stake in C4 Therapeutics

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have disclosed a combined beneficial ownership of 9.3% in C4 Therapeutics, Inc. common stock.

Summary

• Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley & Co. LLC, reported beneficial ownership of C4 Therapeutics, Inc. common stock.
• Morgan Stanley beneficially owns 8,974,191 shares, representing 9.3% of the class.
• Morgan Stanley & Co. LLC beneficially owns 8,897,942 shares, representing 9.2% of the class.
• The securities were acquired and are held in the ordinary course of business.
• The acquisition was not for the purpose of changing or influencing control of C4 Therapeutics, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure, as it confirms a significant institutional stake by Morgan Stanley, which can be interpreted as a vote of confidence, without indicating any intent to influence control.

Positives

• A major financial institution, Morgan Stanley, holds a significant stake, potentially indicating institutional confidence in C4 Therapeutics.

Negatives

• No specific negative information is disclosed in this ownership filing.

Risks

• NA

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Chris O'Hara, Authorized Signatory for Morgan Stanley and Morgan Stanley & Co. LLC)

Industry Context

StockSavvy.ai notes that institutional ownership by major financial firms like Morgan Stanley can often be viewed positively by the market, signaling a degree of confidence in the underlying company, C4 Therapeutics, which operates in the biotechnology sector. Such disclosures are standard for large institutional investors crossing certain ownership thresholds.

Comparison to Industry Standards

• NA

Related Party Transactions

• Morgan Stanley & Co. LLC, which beneficially owns 9.2% of C4 Therapeutics, Inc. common stock, is a wholly-owned subsidiary of Morgan Stanley, which beneficially owns 9.3%.

Stakeholder Impact

• Shareholders: May view the significant institutional ownership by Morgan Stanley as a positive signal, potentially increasing confidence in the stock.
• Management: The certification that the stake is not for control purposes indicates no immediate threat of activist intervention from Morgan Stanley.

Key Dates

Recommendation

The filing indicates a significant institutional holding by Morgan Stanley, which is generally a positive signal of confidence. However, as a Schedule 13G, it is purely an ownership disclosure and does not provide new operational or financial performance data for C4 Therapeutics, Inc. Therefore, it primarily reinforces existing sentiment rather than prompting a change in investment thesis. A 'hold' recommendation reflects the stability implied by institutional interest without new catalysts for 'buy' or 'sell'.

Keywords

C4 Therapeutics, Morgan Stanley, Institutional Ownership, Schedule 13G, Common Stock, Biotechnology, Investment, SEC Filing, CTXR